Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
0(0%)
Results Posted
80%(8 trials)

Phase Distribution

Ph not_applicable
1
8%
Ph phase_2
1
8%
Ph phase_3
5
42%
Ph phase_4
2
17%
Ph phase_1
2
17%

Phase Distribution

2

Early Stage

1

Mid Stage

7

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
1(9.1%)
Phase 3Large-scale testing
5(45.5%)
Phase 4Post-market surveillance
2(18.2%)
N/ANon-phased studies
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(10)
Other(2)

Detailed Status

Completed10
unknown2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (18.2%)
Phase 21 (9.1%)
Phase 35 (45.5%)
Phase 42 (18.2%)
N/A1 (9.1%)

Trials by Status

completed1083%
unknown217%

Recent Activity

Clinical Trials (12)

Showing 12 of 12 trials
NCT02325934Phase 1

Bioequivalence of Crushed Stribild With a Normal Breakfast or With Drip Feed Compared to the Whole Tablet

Completed
NCT02251236Not Applicable

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

Completed
NCT02556268Phase 1

Interaction With HIV Antiretroviral Agents

Completed
NCT02477527Phase 4

Atripla to Stribild Switch Study to Evaluate Sleep Disturbances

Completed
NCT01475838Phase 3

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Completed
NCT02283060Phase 4

Sleep and Cognition After Atripla to Stribild Switch

Unknown
NCT01495702Phase 3

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Completed
NCT01106586Phase 3

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Completed
NCT01095796Phase 3

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Completed
NCT02306577

STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY)

Unknown
NCT01533259Phase 3

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Completed
NCT00869557Phase 2

Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12